$CRY (CryoLife Inc.)

$CRY {{ '2016-02-04T19:10:06+0000' | timeago}} • Announcement

$CRY said it sold HeRO Graft product line to $MMSI. $CRY will continue to manufacture HeRO Graft for up to 6 months under transition supply agreement, after which $MMSI will be responsible for manufacturing. $CRY expects to utilize cash proceeds from sale to pay down $75MM term loan and for general corporate purposes.

$ABMD {{ '2017-09-20T21:54:10+0000' | timeago}} • Announcement

$ABMD received US FDA pre-market approval for the Impella RP heart pump. The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, heart transplant, or open-heart surgery.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$BSX {{ '2017-09-19T15:14:32+0000' | timeago}} • Announcement

$BSX announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure decompensation. The data demonstrate alert improves heart failure risk prediction.

$BSX {{ '2017-09-18T14:02:45+0000' | timeago}} • Announcement

$BSX announced results from a 3-year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study. The patients with severe asthma show sustained clinical improvement and the data confirmed long-term effectiveness of Bronchial Thermoplasty.

$MDT {{ '2017-09-18T13:29:52+0000' | timeago}} • Announcement

$MDT announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$LIVN {{ '2017-09-14T20:47:42+0000' | timeago}} • Announcement

$LIVN intends to invest in inorganic opportunities within adjacent and underserved markets. The company expects to achieve revenue growth in the mid-single-digits in the near term and high-single-digits in the long term. $LIVN anticipates compounded annual earnings per share growth in the low- to mid-teens from 2017 to 2022.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$BABY {{ '2017-09-11T14:02:00+0000' | timeago}} • Announcement

$BABY has agreed to acquire certain neurosurgery business assets from $IART for $47.5MM. The divestiture by $IART is contingent on the consummation of its proposed acquisition of Codman Neurosurgery. Both transactions are expected to close in October 2017. $BABY expects the acquisition to be immediately accretive to non-GAAP earnings.

$MDT {{ '2017-09-11T12:01:51+0000' | timeago}} • Announcement

$MDT voluntarily recalls specific lots of infusion sets used with all models of Medtronic insulin pumps due to a certain discontinued component. The recall comes after reports from patients that a component, the vent membrane, may be susceptible to being blocked by fluid during priming and fill-tubing, which can lead to over-delivery of insulin.

$BABY {{ '2017-09-11T11:55:35+0000' | timeago}} • Announcement

$BABY has entered into a definitive agreement with $IART, under which $BABY will acquire certain neurosurgery business assets from $IART for $47.5MM. The transaction is expected to close in October 2017, after regulatory clearance.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ABMD (ABIOMED, Inc.)
Thursday, July 27 2017 - 12:00pm
BSX (Boston Scientific Corporation)
Thursday, July 27 2017 - 12:00pm
SNN (Smith & Nephew plc)
Thursday, July 27 2017 - 8:00am

AlphaGraphics you may like